Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) – Stock analysts at William Blair cut their Q1 2024 earnings per share estimates for Viking Therapeutics in a report released on Wednesday, February 7th. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of ($0.27) per share for the quarter, down from […]
Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug's potential competitiveness in a crowded field of contenders.
12.12.2023 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and . Seite 1
Brokers Offer Predictions for Viking Therapeutics, Inc s FY2023 Earnings (NASDAQ:VKTX) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.